POLG2 Protein

POLG2 Protein

Overview

POLG2 (DNA Polymerase Gamma 2) is the accessory subunit of mitochondrial DNA polymerase gamma (Pol γ), the sole replicative polymerase responsible for mitochondrial DNA (mtDNA) synthesis and maintenance in human cells. Encoded by the POLG2 gene located on chromosome 17q24.1, POLG2 forms a heterotrimeric complex with the catalytic POLG1 subunit (two copies of POLG2 associate with one POLG1 molecule). This protein is essential for mtDNA replication fidelity, proofreading, and processivity, and its dysfunction contributes to mitochondrial genetic disorders and neurodegeneration. The POLG2 protein comprises approximately 599 amino acids and functions as a processivity factor that dramatically increases the catalytic efficiency of DNA polymerization by Pol γ.

Function and Biology

POLG2 functions as a processivity factor that enhances DNA replication efficiency by increasing the binding affinity of Pol γ to mtDNA and extending polymerization without dissociation from the template strand. The POLG2-POLG1 interaction forms the core 3D5 exonuclease domain architecture, which provides 3' to 5' proofreading exonuclease activity critical for maintaining mtDNA sequence fidelity. Specifically, POLG2 stabilizes the catalytic POLG1 polymerase domain and facilitates the translocation between polymerase and exonuclease modes during DNA synthesis.

POLG2 Protein

Overview

POLG2 (DNA Polymerase Gamma 2) is the accessory subunit of mitochondrial DNA polymerase gamma (Pol γ), the sole replicative polymerase responsible for mitochondrial DNA (mtDNA) synthesis and maintenance in human cells. Encoded by the POLG2 gene located on chromosome 17q24.1, POLG2 forms a heterotrimeric complex with the catalytic POLG1 subunit (two copies of POLG2 associate with one POLG1 molecule). This protein is essential for mtDNA replication fidelity, proofreading, and processivity, and its dysfunction contributes to mitochondrial genetic disorders and neurodegeneration. The POLG2 protein comprises approximately 599 amino acids and functions as a processivity factor that dramatically increases the catalytic efficiency of DNA polymerization by Pol γ.

Function and Biology

POLG2 functions as a processivity factor that enhances DNA replication efficiency by increasing the binding affinity of Pol γ to mtDNA and extending polymerization without dissociation from the template strand. The POLG2-POLG1 interaction forms the core 3D5 exonuclease domain architecture, which provides 3' to 5' proofreading exonuclease activity critical for maintaining mtDNA sequence fidelity. Specifically, POLG2 stabilizes the catalytic POLG1 polymerase domain and facilitates the translocation between polymerase and exonuclease modes during DNA synthesis.

POLG2 is highly expressed in tissues with elevated metabolic demands, particularly neurons, cardiac myocytes, and hepatocytes—organs dependent on oxidative phosphorylation and continuous ATP production. The protein localizes exclusively to mitochondria through an N-terminal mitochondrial targeting sequence. During mtDNA replication, POLG2 recruits accessory proteins including Twinkle helicase (encoded by TWNK) and mitochondrial single-stranded DNA-binding protein (mtSSB, encoded by SSBP1), which together facilitate processive DNA synthesis and maintenance of mtDNA integrity.

Role in Neurodegeneration

Mutations in POLG2 cause Autosomal Recessive Progressive External Ophthalmoplegia (arPEO) and related mitochondrial disorders characterized by progressive neurological decline. The most common pathogenic variants impair either the catalytic processivity function or the stability of the Pol γ holoenzyme complex. mtDNA depletion or accumulation of point mutations results from compromised POLG2 function, leading to impaired oxidative phosphorylation and energetic failure in neurons—a mechanism particularly damaging to postmitotic cells unable to divide and dilute defective mtDNA.

Progressive mtDNA mutations and reduced mtDNA copy number downstream of POLG2 deficiency manifest as a spectrum of neurodegenerative phenotypes. Neurons experience profound bioenergetic stress due to complex I-IV dysfunction in the electron transport chain, leading to excessive reactive oxygen species (ROS) production. This oxidative stress overwhelms mitochondrial antioxidant defenses including superoxide dismutase 2 (SOD2) and catalase, triggering secondary neurodegeneration through oxidative damage to proteins, lipids, and nucleic acids.

Molecular Mechanisms

POLG2 mutations impair mtDNA maintenance through several mechanisms: (1) reduced catalytic processivity, decreasing the number of nucleotides synthesized per binding event; (2) destabilization of the Pol γ heterotrimer, reducing holoenzyme assembly efficiency; (3) compromised exonuclease proofreading capacity, increasing mtDNA mutation rate; and (4) impaired interaction with mtDNA replication accessory factors including Twinkle helicase and mtSSB.

Loss of POLG2 function triggers mitochondrial quality control responses including mitophagy (selective autophagy of defective mitochondria) and activation of the mitochondrial unfolded protein response (UPRmt) through ATF4 and ATF5 transcription factors. Chronic mtDNA instability activates innate immune signaling through cGAS-STING pathways, amplifying neuroinflammation through type I interferon production and microglial activation—a secondary mechanism contributing to neuronal death.

Clinical and Research Significance

POLG2 mutations represent important genetic causes of mitochondrial neurodegenerative disease, with particular prevalence in progressive external ophthalmoplegia cohorts. Diagnostic sequencing of POLG2 identifies compound heterozygous mutations in affected individuals, enabling genetic counseling and prognosis stratification. Research into POLG2 biology has illuminated mtDNA replication mechanisms and generated insights applicable to neurodegenerative disease pathogenesis broadly. Therapeutic interventions targeting mtDNA replication fidelity through POLG2 modulation, or enhancing mitochondrial quality control, represent promising strategies for treatment.

Related Entities

• POLG1 — catalytic subunit of mitochondrial DNA polymerase gamma
• **TWNK